Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers ...

In fact, last year Lilly's medication -- called tirzepatide, which treats both type 2 diabetes and obesity -- became the best ...

As with so much of Lilly’s recent advertising work, Wieden+Kennedy’s specific style and tone have helped differentiate its commercials from that of other pharma companies.

This history of rapid acceleration suggests that Eli Lilly is primed for another massive breakout as new catalysts emerge.

Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.

By Padmanabhan Ananthan and Sriparna Roy Feb 9 (Reuters) - Eli Lilly will buy Orna Therapeutics for up to $2.4 billion in ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Eli Lilly and Innovent Biologics have deepened their ties with a new type of deal. | Eli Lilly and Innovent Biologics have ...

Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders. | Eli Lilly ...

Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of ...

Eli Lilly to buy Orna Therapeutics, which focuses on ‘in vivo’ CAR-T for autoimmune diseases, for $2.4 billion ...

Novo Nordisk just did Eli Lilly stock a huge favor.